Actively Recruiting

Early Phase 1
Age: 18Years - 45Years
All Genders
ID06267183

A Phase I, Single-center, Randomized, Double-blind, Single-dose, Dose-ascending, Placebo-controlled Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers

Led by Shanghai Synvida Biotechnology Co.,Ltd. · Updated on 2026-03-11

53

Participants Needed

1

Research Sites

4 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the safety, tolerability, pharmacokinetics (PK), and immune response of a drug called SV001 compared to a placebo in healthy adult volunteers from China. This early phase 1, randomized, double-blind, and placebo-controlled study aims to understand how SV001 behaves in the body and whether it causes any adverse effects. The study focuses on adults aged 18 to 45 years who are in good health. Participants will receive a single dose of either SV001 or a placebo. The study uses a dose-escalation design, meaning doses may increase to assess safety. The trial is conducted at a single center and uses a quadruple-blind method where participants, care providers, investigators, and outcome assessors are unaware of which treatment is given. The intervention period includes administration of the study drug followed by monitoring. During the study, participants will undergo various assessments including monitoring for any treatment-emergent adverse events, measuring drug levels in the blood over time, and checking for immune responses to SV001. These evaluations will take place over approximately one year. Researchers will also monitor participants' overall health, respiratory function, and conduct laboratory tests to ensure safety throughout the trial.

CONDITIONS

Brief Title

A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers.

Who Can Participate

Age: 18Years - 45Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Subjects must fully understand the trial and volunteer by signing the Informed Consent Form
  • Body Mass Index between 19 and 26 kg/m2, with males weighing at least 50 kg and females at least 45 kg
  • Subjects must be in good health as judged by the investigator
  • Reliable contraception must be used during and after the trial
Not Eligible

You will not qualify if you...

  • History of drug or other substance anaphylaxis
  • Respiratory symptoms or abnormal respiratory tract
  • Current oral disease that may affect use of trial drug or devices
  • Other diseases with abnormal clinical manifestations
  • History of drug abuse or positive urine narcotics test
  • Smoking more than 5 cigarettes a day before screening
  • Consuming more than 14 units of alcohol per week or positive breath alcohol test
  • Recent severe disease or major surgery or expected major surgery during trial
  • Use of other drugs within a certain period before investigational drug
  • FEV1 or FVC less than or equal to 80% predicted value at screening
  • Positive antibody tests for HIV, Hepatitis B, Hepatitis C, or Treponema Pallidum
  • Difficulty in venous blood collection or history of blood phobia
  • Female subjects pregnant or lactating during screening or baseline
  • Participation in other drug trials or drug use within a certain period before investigational drug
  • History of blood donation or blood loss over 400 mL before screening
  • Any other condition deemed inappropriate by the investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Treatment

Duration - Single dosing with approximately 1 year of follow-up monitoring

Participants receive a single dose of SV001 or placebo to evaluate safety, tolerability, and pharmacokinetics.

1 baseline visit and multiple follow-up visits over approximately 1 year

Trial Site Locations

Total: 1 location

1

Shanghai Xuhui District Central Hospital

Shanghai, China

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

An Open-label Extension Trial of the Long-term Safety and Ef...

Idiopathic Pulmonary Fibrosis

Actively Recruiting

373 locations

A Randomized, Double-blind, Placebo-controlled, Single and M...

Idiopathic Pulmonary Fibrosis

Actively Recruiting

1 location

An Open-label, Single-group Trial to Evaluate How Pirfenidon...

Idiopathic Pulmonary Fibrosis

Actively Recruiting

3 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here